News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xencor Reports Second Quarter 2017 Financial Results



8/8/2017 12:05:36 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
MONROVIA, Calif., Aug. 7, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2017 and provided a review of business and clinical highlights.

"In the second quarter, we continued to advance our pipeline of wholly-owned and partnered XmAb® antibody drug candidates," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.

Read at PR Newswire


comments powered by Disqus
Xencor
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES